Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis

Open access

Abstract

Background: Epicardial adipose tissue (EAT) plays an important role in cardiometabolic risk. EAT is a modifiable risk factor and could be a potential therapeutic target for drugs that already show cardiovascular benefits. The aim of this study is to evaluate the effect of cardiometabolic drugs on EAT reduction. Methods: A detailed search related to the effect on EAT reduction due to cardiometabolic drugs, such as glucagon-like peptide-1 receptor agonist (GLP-1 RA), sodium-glucose cotransporter-2 inhibitors (SGLT2-i), and statins was conducted according to PRISMA guidelines. Eighteen studies enrolling 1064 patients were included in the qualitative and quantitative analyses. Results: All three analyzed drug classes, in particular GLP-1 RA, show a significant effect on EAT reduction (GLP-1 RA standardize mean difference (SMD) = − 1.005; p < 0.001; SGLT2-i SMD = − 0.552; p < 0.001, and statin SMD = − 0.195; p < 0.001). The sensitivity analysis showed that cardiometabolic drugs strongly benefit EAT thickness reduction, measured by ultrasound (overall SMD of − 0.663; 95%CI − 0.79, − 0.52; p < 0.001). Meta-regression analysis revealed younger age and higher BMI as significant effect modifiers of the association between cardiometabolic drugs and EAT reduction for both composite effect and effect on EAT thickness, (age Z: 3.99; p < 0.001 and Z: 1.97; p = 0.001, respectively; BMI Z: − 4.40; p < 0.001 and Z: − 2.85; p = 0.004, respectively). Conclusions: Cardiometabolic drugs show a significant beneficial effect on EAT reduction. GLP-1 RA was more effective than SGLT2-i, while statins had a rather mild effect. We believe that the most effective treatment with these drugs should target younger patients with high BMI. Graphical Abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-023-01738-2

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Prisma Flow Chart. The flow chart represents the number of studies evaluated according to PRISMA guidelines
Fig. 1 Prisma Flow Chart. The flow chart represents the number of studies evaluated according to PRISMA guidelinesCC BY · PubMed Central
Fig. 2 Forest plots of the cardiometabolic drug effect on the epicardial adipose tissue (EAT) reduction, assessed by ultrasound, computed tomography and magnetic resonance imaging. EAT reduction was evaluated with the standardized difference in means (SMD) between baseline and follow-up. The diamond represents the estimated overall effect, while the squares represent each study with 95% CI
Fig. 2 Forest plots of the cardiometabolic drug effect on the epicardial adipose tissue (EAT) reduction, assessed by ultrasound, computed tomography and magnetic resonance imaging. EAT reduction was evaluated with the standardized difference in means (SMD) between baseline and follow-up. The diamond represents the estimated overall effect, while the squares represent each study with 95% CICC BY · PubMed Central
Fig. 3 Forest plots the effect of cardiometabolic drug on the epicardial adipose tissue thickness reduction assessed by ultrasound. EAT thickness reduction was evaluated with the standardized difference in means (SMD) between baseline and follow-up. The diamond represents the estimated overall effect, while the squares represent each study with 95% CI
Fig. 3 Forest plots the effect of cardiometabolic drug on the epicardial adipose tissue thickness reduction assessed by ultrasound. EAT thickness reduction was evaluated with the standardized difference in means (SMD) between baseline and follow-up. The diamond represents the estimated overall effect, while the squares represent each study with 95% CICC BY · PubMed Central
Fig. 4 Forest plots the effect of cardiometabolic drug on the epicardial adipose tissue thickening at 3- and 6-months follow-up. EAT thickness reduction was evaluated with the standardized difference in means (SMD) between 3 and 6 months of follow-up. The diamond represents the estimated overall effect, while the squares represent each study with 95% CI
Fig. 4 Forest plots the effect of cardiometabolic drug on the epicardial adipose tissue thickening at 3- and 6-months follow-up. EAT thickness reduction was evaluated with the standardized difference in means (SMD) between 3 and 6 months of follow-up. The diamond represents the estimated overall effect, while the squares represent each study with 95% CICC BY · PubMed Central
Fig. 5 Meta-regression analysis. Impact of age on the difference in composite cardiometabolic drugs effect and EAT reduction (A), and cardiometabolic drugs effect and EAT thickness reduction measured ultrasound (B). Impact of BMI on the difference in composite cardiometabolic drugs effect and EAT reduction (C), and cardiometabolic drugs effect and EAT thickness reduction measured ultrasound (D)
Fig. 5 Meta-regression analysis. Impact of age on the difference in composite cardiometabolic drugs effect and EAT reduction (A), and cardiometabolic drugs effect and EAT thickness reduction measured ultrasound (B). Impact of BMI on the difference in composite cardiometabolic drugs effect and EAT reduction (C), and cardiometabolic drugs effect and EAT thickness reduction measured ultrasound (D)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 93

Metadata

Authors
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., Genovese, S., & Poggio, P.
Affiliations
  • Centro Cardiologico Monzino (IT)
  • Federico II University Hospital (IT)
  • Casa di Cura San Michele (IT)
Corresponding author
  • Myasoedova, Veronika A.
  • Poggio, Paolo
Venue
Cardiovascular Diabetology
Published
2023-01-31
Volume
22
Issue
1
Pages
23-23
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4318619190
Cited by
93
References
68
Citations by year
2026: 24 · 2025: 31 · 2024: 24 · 2023: 14
FWCI
4.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministero della Salute (Ricerca Corrente)
  • Fondazione Gigi e Pupa Ferrari (FPF-14)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
epicardial adipose tissue, GLP-1 receptor agonists, SGLT2 inhibitors, statins, EAT thickness, ultrasonic measurement, body mass index, age, effect modifiers, cardiovascular risk
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Humans, Obesity, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12933-023-01738-2
The paper
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., Genovese, S., & Poggio, P. (2023). Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-023-01738-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.